Photo: Wikimedia Commons
The Philadelphia jury deliberating in the first punitive damages trial over Johnson & Johnson's conduct in marketing the antispychotic drug Risperdal has slammed the company with an $8 billion verdict.
October 08, 2019 at 06:07 PM
1 minute read
The original version of this story was published on The Legal Intelligencer
The Philadelphia jury deliberating in the first punitive damages trial over Johnson & Johnson’s conduct in marketing the antispychotic drug Risperdal has slammed the company with an $8 billion verdict.
The award comes after more than three weeks of trial in the case Murray v. Janssen Pharmaceuticals. The award is the largest to date in the Risperdal litigation, which consists of nearly 7,000 cases pending in the Philadelphia Court of Common Pleas.
Presented by BigVoodoo
Join the industry's top owners, investors, developers, brokers & financiers at THE MULTIFAMILY EVENT OF THE YEAR!
Law firms & in-house legal departments with a presence in the middle east celebrate outstanding achievement within the profession.
The premier educational and networking event for employee benefits brokers and agents.
Atlanta s John Marshall Law School is seeking to hire one or more full-time, visiting Legal WritingInstructors to teach Legal Research, Anal...
Lower Manhattan firm seeks a premises liability litigator (i.e., depositions, SJ motions, and/or trials) with at least 3-6 years of experien...
At NJM, a top-rated insurance company, we are seeking an Attorney on our Workers Compensation legal team with between 3 and 5 years of expe...
MELICK & PORTER, LLP PROMOTES CONNECTICUT PARTNERS HOLLY ROGERS, STEVEN BANKS, and ALEXANDER AHRENS
